Osage University Partners (OUP) is a venture capital firm dedicated to investing exclusively in startups that commercialize university research. Founded in 2009, OUP collaborates with over 100 leading universities and research institutions to identify and support innovative companies emerging from academic research. By partnering with these institutions, OUP not only invests in promising startups but also shares profits with affiliated universities, thereby fostering and expanding the university entrepreneurial ecosystem.

The firm has raised multiple funds, including a $100 million debut fund in 2011, a $215 million fund in 2015, and a $273 million fund in 2019, bringing its total assets under management to approximately $600 million. OUP's investment strategy spans various sectors, including life sciences, technology, and advanced materials, and covers all stages of company development, from seed to late-stage/pre-IPO. The firm's portfolio includes notable companies such as Aptinyx, Biohaven Pharma, Kura Oncology, Homology Medicines, Selecta Biosciences, Spero Therapeutics, and Synthorx.

OUP's unique model leverages its deep relationships with university technology transfer offices to access co-investment rights in university spinouts, allowing it to invest in a diverse range of innovative companies emerging from academic research.